


CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:


- 5 A is selected from C₆-C₁₄-aryl, 5- to 14-membered heteroaryl and 3- to 14-membered heterocyclyl;
- B is
- (i) C₆-C₁₄-aryl; and L¹ is -O-; or
- (ii) 5- to 14-membered heteroaryl; and L¹ is a covalent bond or -O-;
- 10 m is 0, n is 0 or 1 and X is CR⁸; or
- m is 1, n is 1 or 2 and X is CR⁸ or N;
- R¹, R², and R³ are independently selected from hydrogen and C₁₋₆-alkyl;
- R⁴, R⁵, R⁶ and R⁷ are independently selected from hydrogen, halogen, cyano, hydroxy, C₁₋₆-alkoxy, halo-C₁₋₆-alkoxy, amino-C₁₋₆-alkoxy, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkylsulfonyl, SF₅, carbamoyl, C₃₋₁₀-cycloalkyl-C₁₋₆-alkoxy-, C₁₋₆-alkyl-NH-C(O)-, C₁₋₆-alkyl-C(O)-NH-, and C₃₋₁₀-cycloalkyl, wherein each C₃₋₁₀-cycloalkyl is optionally substituted with 1-2 substituents selected from C₁₋₆-alkyl and halo-C₁₋₆-alkyl; and
- 15 R⁸ is selected from hydrogen, halogen, hydroxy, halo-C₁₋₆-alkyl, and C₁₋₆-alkyl.
- 20 2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is C₆-C₁₄-aryl or 5- to 14-membered heteroaryl.
3. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is phenyl or pyridyl.
4. The compound of formula (I) according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein
- 25 B is
- (i) phenyl; and L¹ is -O-; or

- 97 -

- (ii) selected from oxadiazolyl, pyridazinyl, pyridyl, and thiazolyl; and L¹ is a covalent bond or -O-.
5. The compound of formula (I) according to any one of claims 1-4, wherein:
m is 0, n is 0 and X is CR⁸; or
5 m is 1, n is 1 and X is CR⁸ or N.
6. The compound of formula (I) according to any one of claims 1-4, wherein m is 0, n is 0 and X is CR⁸.
7. The compound of formula (I) according to any one of claims 1-6, wherein R¹ is hydrogen.
- 10 8. The compound of formula (I) according to any one of claims 1-7, wherein R² is hydrogen.
9. The compound of formula (I) according to any one of claims 1-8, wherein R³ is hydrogen.
10. The compound of formula (I) according to any one of claims 1-9, wherein R⁴ is
15 hydrogen.
11. The compound of formula (I) according to any one of claims 1-10, wherein R⁵ is hydrogen.
12. The compound of formula (I) according to any one of claims 1-11, wherein R⁶ is selected from hydrogen, halogen, cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, and C₁₋₆-alkylsulfonyl.
20
13. The compound of formula (I) according to any one of claims 1-11, wherein R⁶ is selected from hydrogen, halogen, cyano, and C₁₋₆-alkyl.
14. The compound of formula (I) according to any one of claims 1-11, wherein R⁶ is selected from hydrogen, fluoro, chloro, cyano, methyl, and 2,2-dimethylpropyl.
- 25 15. The compound of formula (I) according to any one of claims 1-14, wherein R⁷ is selected from hydrogen, halogen, and C₁₋₆-alkyl.
16. The compound of formula (I) according to any one of claims 1-14, wherein R⁷ is selected from hydrogen, fluoro and methyl.

- 98 -

17. The compound of formula (I) according to any one of claims 1-16, wherein R^8 is hydrogen or hydroxy.
18. The compound of formula (I) according to claim 1, wherein the compound of formula (I) is a compound of formula (IIa), or a pharmaceutically acceptable salt thereof,



wherein:

A is C_6 - C_{14} -aryl or 5- to 14-membered heteroaryl;

B is

- (i) C_6 - C_{14} -aryl; and L^1 is $-O-$; or
- (ii) 5- to 14-membered heteroaryl; and L^1 is a covalent bond or $-O-$;

m is 0, n is 0 and X is CR^8 ; or


m is 1, n is 1 and X is CR^8 or N;

R^6 is selected from hydrogen, halogen, cyano, C_{1-6} -alkyl, C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, and C_{1-6} -alkylsulfonyl;

R^7 is selected from hydrogen, halogen, and C_{1-6} -alkyl; and

R^8 is selected from hydrogen and hydroxy.

19. The compound of formula (I) according to claim 1, wherein the compound of formula (I) is a compound of formula (IIb), or a pharmaceutically acceptable salt thereof,



wherein:

A is C_6 - C_{14} -aryl or 5- to 14-membered heteroaryl;

B is

- (i) C_6 - C_{14} -aryl; and L^1 is $-O-$; or
- (ii) 5- to 14-membered heteroaryl; and L^1 is a covalent bond or $-O-$;


R^6 is selected from hydrogen, halogen, cyano, and C_{1-6} -alkyl;

- 99 -

R^7 is selected from hydrogen, C_{1-6} -alkyl, and halogen; and

R^8 is selected from hydrogen and hydroxy.

20. The compound of formula (I) according to claim 1, wherein the compound of formula (I) is a compound of formula (IIb), or a pharmaceutically acceptable salt thereof,



wherein:

A is phenyl or pyridyl;

B is

- 10 (i) phenyl; and L^1 is $-O-$; or
 (ii) selected from oxadiazolyl, pyridazinyl, pyridyl, and thiazolyl; and L^1 is a covalent bond or $-O-$;

R^6 is selected from hydrogen, fluoro, chloro, cyano, methyl, and 2,2-dimethylpropyl;

15 R^7 is selected from hydrogen, methyl, and fluoro; and

R^8 is selected from hydrogen and hydroxy.

21. The compound of formula (I) according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, selected from:

- (4aR,8aS)-6-(3-(4-Phenoxyphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- 20 (4aR,8aS)-6-[3-[4-(2-Chlorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-(4-Pyrimidin-2-yloxyphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-[3-[4-[(2-Methyl-3-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(4-Methylpyrimidin-2-yl)oxyphenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 30 (4aR,8aS)-6-[3-(4-Pyridazin-3-yloxyphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (4aR,8aS)-6-[3-[4-[(4-Methyl-3-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[(5-Fluoro-3-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[3-[4-[(5-Chloro-3-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Pyridyloxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(4-Methylpyridazin-3-yl)oxyphenyl]azetidine-1-carbonyl]-
10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Chloropyridazin-4-yl)oxyphenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(4-Methoxypyrimidin-2-yl)oxyphenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 (4aR,8aS)-6-[3-[4-[4-(Trifluoromethyl)pyrimidin-2-yl]oxyphenyl]azetidine-1-
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Fluorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(4-Fluorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
20 hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2,4-Difluorophenoxy)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2-Fluorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-[3-[4-(4-Chlorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Chlorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2-Methylphenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
30 hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[3-(Trifluoromethyl)phenoxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 2-[4-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-
carbonyl]azetidin-3-yl]phenoxy]benzonitrile;

- (4aR,8aS)-6-[3-[4-(2-Chloropyrimidin-4-yl)oxyphenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (+)-(4aR,8aS)-6-[3-[4-(4-Cyclopropylpyrimidin-2-yl)oxyphenyl]azetidine-1-
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[3-[4-[(6-Methyl-2-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[(4-chloro-3-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[(3-Fluoro-4-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one ;
- (+)-(4aR,8aS)-6-[3-[4-(2-Methylsulfonylpyrimidin-4-yl)oxyphenyl]azetidine-1-
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one ;
- (4aR,8aS)-6-[3-[4-[(3,6-Dimethyl-2-pyridyl)oxy]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 (4aR,8aS)-6-[3-[4-(1H-Pyrazol-5-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[2-(2,2-Dimethylpropyl)pyrazol-3-yl]phenyl]azetidine-1-
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[1-(2,2-Dimethylpropyl)pyrazol-3-yl]phenyl]azetidine-1-
20 carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(3-Chloro-2-pyridyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2,4-Dimethyloxazol-5-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-[3-[4-(3,5-Dimethylpyrazol-1-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[3-(2,2-Dimethylpropyl)triazol-4-yl]phenyl]azetidine-1-
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[5-(2,2-Dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl]azetidine-1-
30 carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[5-(2,2-Dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl]azetidine-1-
carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-[2-(2-Fluoroethyl)pyrazol-3-yl]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

- (4aR,8aS)-6-[3-[4-[1-(2-Fluoroethyl)pyrazol-4-yl]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(4-Methyl-1,3-thiazol-2-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 5 (4aR,8aS)-6-[3-[4-(1-Methylpyrazol-3-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(6-Fluoropyridin-3-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2-Fluoropyridin-4-yl)phenyl]azetidine-1-carbonyl]-
10 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(1-Methylpyrazol-4-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-[4-(2-Methylpyrazol-3-yl)phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 15 (4aR,8aS)-6-[3-[5-(4-Fluorophenoxy)-2-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-(3-(6-(4-Fluorophenoxy)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(6-(4-(Trifluoromethoxy)phenoxy)pyridin-3-yl)azetidine-1-
20 carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(6-(4-Chlorophenoxy)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[3-[4-(3,6-Dimethylpyridazin-4-yl)oxyphenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- 25 (4aR,8aS)-6-(3-(6-(2-Chlorophenoxy)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-(3-(6-(3-Chlorophenoxy)pyridin-3-yl)azetidine-1-carbonyl)hexahydro-
2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;
- (4aR,8aS)-6-[4-[4-(4-Fluorophenoxy)phenyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-
30 hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-Hydroxy-3-(4-phenoxyphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-
hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[3-Hydroxy-3-(5-phenoxy-2-pyridyl)azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[4-(4-Phenoxyphenyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and
 (4aR,8aS)-6-[4-(4-Phenoxyphenyl)piperazine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.

- 5 22. The compound of formula (I) according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, selected from:

(4aR,8aS)-6-(3-(4-Phenoxyphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one;

(4aR,8aS)-6-[3-[4-(3-Chloropyridazin-4-yl)oxyphenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[4-(2,4-Difluorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[4-(2-Fluorophenoxy)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

15 2-[4-[1-[(4aR,8aS)-3-Oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azetidin-3-yl]phenoxy]benzonitrile;

(4aR,8aS)-6-[3-[4-(3-Chloro-2-pyridyl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[4-[5-(2,2-Dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[4-(4-Methyl-1,3-thiazol-2-yl)phenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[5-(4-fluorophenoxy)-2-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;


25 (4aR,8aS)-6-[3-[4-(3,6-dimethylpyridazin-4-yl)oxyphenyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

(4aR,8aS)-6-[3-[6-(2-chlorophenoxy)-3-pyridyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and

(4aR,8aS)-6-[3-hydroxy-3-(4-phenoxyphenyl)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.
23. A process of manufacturing the compounds of formula (I) according to any one of claims 1 to 22, or pharmaceutically acceptable salts thereof, comprising:


- 104 -

reacting 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-ones **1**,
 wherein R¹ and R² are as defined in any one of claims 1 to 22,



5

with a heterocyclic amine **2**, wherein A, B, L¹, X, m, n, and R³ to R⁷ are as
 defined in any one of claims 1 to 22

**2**

in the presence of a base and a urea forming reagent,
 to form said compounds of formula (I) or a pharmaceutically acceptable salt thereof.

24. A compound of formula (I) according to any one of claims 1 to 22, or a
 10 pharmaceutically acceptable salt thereof, when manufactured according to the
 process of claim 23.
25. A compound of formula (I) according to any one of claims 1 to 22 and 24, or a
 pharmaceutically acceptable salt thereof, wherein said compound of formula (I) or
 pharmaceutically acceptable salt thereof has an IC₅₀ for monoacylglycerol lipase
 15 below 10 μM.
26. A compound of formula (I) according to any one of claims 1 to 22, 24 and 25, or a
 pharmaceutically acceptable salt thereof, for use as therapeutically active substance.
27. A pharmaceutical composition comprising a compound of formula (I) according to
 any one of claims 1 to 22, 24 and 25, or a pharmaceutically acceptable salt thereof,
 20 and a therapeutically inert carrier.
28. The use of a compound of formula (I) according to any one of claims 1 to 22, or a
 pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
 according to claim 27 for the treatment or prophylaxis of neuroinflammation,

- 105 -

neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

29. The use of a compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
5 according to claim 27 for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated
10 with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
30. A compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 27 for use in the treatment or prophylaxis of neuroinflammation,
15 neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
31. A compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 27 for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's
20 disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or
25 visceral pain in a mammal.
32. The use of a compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
- 30 33. The use of a compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the

- 106 -

- 5 treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- 10 34. A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, and/or inflammatory bowel disease in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 27 to the mammal.
- 15 35. A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain in a mammal, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition according to claim 27 to the mammal.
- 20 36. The invention as described hereinbefore.